ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
21/03/2025
Voltar para busca
Dado oficial do USPTO
TRANSINE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
31
Atualização mais recente
27/03/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42
Data de depósito
11/02/2021
Data de registro
16/08/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
16/08/2022
Última transação
27/03/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
98
Localização do titular
GB
Examinador
O'BRIEN, ELIZABETH
Unidade examinadora
L50
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Harness Therapeutics Limited
Transine Therapeutics Limited
Representantes
Rebecca Liebowitz Venable LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemical preparations for scientific purposesother than for medical or veterinary use; chemicals for research usenucleic acid sequences for laboratory or research use; enzymes for research use; DNA and RNA for research usenucleic acid sequences for laboratory usenucleic acid sequences for other than medical and veterinary purposes; chemicals for use in the preparation and creation of DNA and RNAreagents for scientific purposesother than for medical or veterinary use; enzymes for use in the preparation and creation of DNA and RNAenzymes for scientific and research purposes; molecular biology research tools in the nature of biologicalchemical and biochemical reagents for research use
Classe 5
Pharmaceutical preparations for the treatment and prevention of ophthalmological conditionshearing losshematologic diseasesimmune response disordersneurological disordersrespiratory diseasesfibrosishepatic diseasesrenal diseasesdiseases of the pancreasmetabolic diseasesgenetic conditionscancerinfectious diseases and cardiovascular diseases; medical and veterinary preparations for therapeutic purposes for the treatment and prevention of ophthalmological conditionshearing losshematologic diseasesimmune response disordersneurological disordersrespiratory diseasesfibrosishepatic diseasesrenal diseasesdiseases of the pancreasmetabolic diseasesgenetic conditionscancerinfectious diseases and cardiovascular diseases; biologicalchemical and biochemical reagentsDNA and RNA sequences and gene editing enzymesall for medical use; DNA and RNA products for medical usenucleic acid sequences for medical purposes; therapeutic DNA and RNAnucleic acid sequences for medical purposes
Classe 42
Scientific and technological services and research and design relating theretonamely scientific research services in the field of genomics; medical research services including the manipulation of biological reagents to be used for medical or therapeutic purposes; chemical and biological analysis and research services; scientific research into DNA and RNA; research and development into the creation of DNA and RNA; researchdevelopmenttesting and analysis for scientific research purposes in the field of genomicsDNA and RNA sequencinggene synthesisgene identificationgene cloninggene expressiongene mapping; scientific research in the field of molecular biologynext generation sequencinghigh-throughput sequencing and bioinformatics; gene editing services for scientific research purposes; DNA and RNA modelling servicesnamely genetic mapping for scientific purposes; gene engineering services; research and development services in the creation of genome libraries or collections of biologicals including chemicals and compounds; creating and providing databases or collections of information on normal and mutated genes for scientific research purposes; scientific services relating to the discoverypreclinical and clinical development of therapeutic productsnamely therapeutic DNA and RNA; consultancy and advisory services relating to the aforesaid services; research and development of synthetic DNARNAgenes and oligonucleotides for others
Publicações
Histórico de despachos e eventos da marca no USPTO.
31 publicações encontradas
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
02/03/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
21/12/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
26/11/2022
FIMP
FINAL DISPOSITION PROCESSED
26/11/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
16/11/2022
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
26/10/2022
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
16/08/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
16/08/2022
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
20/06/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
31/05/2022
PUBO
PUBLISHED FOR OPPOSITION
31/05/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/05/2022
ALIE
ASSIGNED TO LIE
25/04/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
22/04/2022
DOCK
ASSIGNED TO EXAMINER
25/03/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
16/03/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
15/03/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
15/03/2022
RFNT
REFUSAL PROCESSED BY IB
04/10/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
16/09/2021
RFRR
REFUSAL PROCESSED BY MPU
16/09/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/09/2021
CNRT
NON-FINAL ACTION WRITTEN
01/09/2021
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
27/08/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
13/08/2021
CNRT
NON-FINAL ACTION WRITTEN
12/08/2021
MAFR
APPLICATION FILING RECEIPT MAILED
10/08/2021
DOCK
ASSIGNED TO EXAMINER
09/08/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/08/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
29/07/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace TRANSINE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.